Medicus Pharma's 'Savvy' Antev Deal De-Risks Pipeline Expansion, Enhances Near-Commercial Portfolio

Why did Coinbase join the S&P 500? How will US-China tariff rollback impact markets? What caused Amazon to partner with FedEx? Why are pharmaceutical stocks sliding today? How will Trump’s drug price order affect pharma? Why did Dow surge after US-China tariff deal? What are the implications of Nissan’s job cuts? How did US-China trade truce impact oil prices? Why is McDonald’s hiring 375,000 workers this summer?

Medicus Pharma's 'Savvy' Antev Deal De-Risks Pipeline Expansion, Enhances Near-Commercial Portfolio

benzinga.com/general/biotech/25/05/45357142/medicus-pharmas-savvy-antev-deal-de-risks-pipeline-expansion-enhances-near-commercial-portfolio

In April, Medicus Pharma Ltd. (NASDAQ:MDCX) agreed to acquire all of Antev’s issued and outstanding shares on a share exchange.
Antev is a clinical-stage biotech company developing Teverelix, a next-generation GnRH antagonist, as the first in-market product for cardiovascular high-risk…

This story appeared on benzinga.com, 2025-05-12 18:20:56.